Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $290.12M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.10M
Average 1.60M
Returns on capital
Autolus Therapeutics plc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-161.8%
avg -65.2%
ROIC
-51.5%
avg -46.1%
ROA
-48.9%
avg -34.9%
Analysis
ROA is currently the strongest return metric at -48.9% versus its period average of -34.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Christian Martin Itin | Chief Executive Officer & Director | USD 2.68M | 62 | — | — |
Chris Williams | Senior VP & Chief Business Development Officer | — | 46 | — | — |
Martin Pule MBBS | Founder, Senior Vice President & Chief Scientific Officer | — | 54 | — | — |
Matthias Will | Senior Vice President & Chief Development Officer | — | 53 | 83.30K | 0.03% |
Alexander Swan | Senior Vice President & Chief Human Resources Officer | — | 61 | 16.47K | <0.01% |
Alex Driggs | Senior Vice President of Legal Affairs & General Counsel and Secretary | — | 50 | 6.00K | <0.01% |
Christopher Vann | Senior Vice President & Chief Operating Officer | — | 61 | — | — |
Patrick McIlvenny | Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer | — | 46 | — | — |
Robert F. Dolski | Senior Vice President & Chief Financial Officer | — | 55 | — | — |
Miranda Neville | Senior VP & Chief Technology Officer | — | 51 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$15,681.57
Net Transaction Value
−$15,681.57
Net selling
Most Active
Piccina Cintia
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 2, 26Sep 2, 2026 | Piccina Cintia Direct | Sell | $15.7K$15,681.57 |
Summary
Insiders reported 0 buys worth $0.00 and 1 sells worth $15,681.57 over the last 12 months. That adds up to net selling of $15,681.57. Piccina Cintia was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +130.2% | +51.0% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +130.2% over three years. Forward estimates point to Revenue at +51.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Autolus Therapeutics plc compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about AUTL's management, answered from reported figures.
Who manages AUTL?
Autolus Therapeutics plc (AUTL) lists 10 active executives. The top listed executive is Christian Martin Itin, Chief Executive Officer & Director.
Are AUTL insiders buying or selling?
Recent insider activity shows net buying of $719,593.43.
Continue the stock analysis
Jump to another research area for this company.